Celltrion: Takeda acquisitions and new plant development

Home/Pharma News | Posted 15/01/2021 post-comment0 Post your comment

Celltrion completed the acquisition of selected primary care assets from Takeda Pharmaceutical Company Limited in the Asia Pacific region in November 2020. In addition, the company announced it will be building a new biopharmaceutical plant and a global biotechnology research centre in Songdo, Incheon, South Korea.

142 AA010936

Acquisition of Takeda products
For a price of US$278 million, Celltrion has now acquired 18 small molecule products from Takeda in the Asia Pacific area. This means that Celltrion has ownership of the rights to patents, trademarks and sales of the products sold in the following markets: South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia and Australia.

The products include prescription medicines such as Nesina, Actos and Edarbi. They expand the company’s portfolio of high-quality originator products that are made in Korea. In addition, they will strengthen Celltrion’s position in the global pharmaceutical’s market.

A third biopharmaceuticals plant
The new 60,000-liter plant will be Celltrion’s third biopharmaceuticals plant and will increase the company’s capacity to 250,000 liters annually. It will have a multi-type production and supply system and the site will also include a one-stop research centre for complex R & D, process development and clinical practice. With an investment of US$453.3 million, it is hoped that the plant will begin producing in 2024.

The plant will have eight 7,500 liters incubators which will allow flexible production of high volumes of biopharmaceutical products. In addition, the plant is likely to create 3,000 jobs.

Celltrion continues to grow its biosimilars portfolio and is set to launch many new products in addition to its biosimilars of Herceptin (trastuzumab) [2] and Remicade (infliximab) [3].

Related articles
Biosimilar advances for Celltrion Healthcare

WHO prequalifies Celltrion’s trastuzumab biosimilar Herzuma

Biosimilar pipelines for Korean firms looking healthy

South Korea increases investment in biologicals


To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.



Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latin Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

1. GaBI Online - Generics and Biosimilars Initiative. Clinical trials for trastuzumab biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 15]. Available from: www.gabionline.net/Biosimilars/General/Clinical-trials-for-trastuzumab-biosimilars 
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of trastuzumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 15]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-trastuzumab  
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of infliximab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 15]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-infliximab 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010